Biotech Values

[BioSpecialist]

Senetek will be the next Psivida !!!!

THIS UNDERVALUED STOCK IS FLYING UNDER RADAR !!!

Senetek (SNKTY.OB)

Market Cap : 9 M$
Cash : 13 M$ (NO DEBT)
Price : 1,20 $

Shares Out : 7,65 Mio

Pipeline
http://www.senetekplc.com/view_our_pipeline.asp

Analyst Report ..Read
http://www.senetekplc.com/SenetekPLC-IntelligenceDynamicsResearchReport.pdf


Senetek PLC
(OTC Bulletin Board: SNKTY.OB)
Senetek is a Life Sciences company engaged in the development of technologies
that target the science of healthy aging. The Company’s extensive research
collaborations have resulted in a strong pipeline of patented compounds and
products with broad therapeutic applications and a leading presence in
dermatology. Senetek collaborates with established specialty pharmaceutical
companies in the final development and marketing of its proprietary products, most
recently resulting in the development of the best-selling anti-aging product sold in
the North American physician market.
Lead Products
Pyratine-6™
(0.1% Furfuryl Tetrahydropyranyladenine)
The first in Senetek’s new generation cytokinin pipeline to complete development,
Pyratine-6™ has demonstrated, through clinical trials, superior results and faster
onset of action in treating photodamaged skin when compared to Senetek’s highly
successful predecessor compounds.
In September 2008, Senetek launched the Pyratine-6™ family of products in the
North America Physician market.
The Company is actively seeking marketing collaboration agreements for other
geographies.
Pyratine XR™
(0.125% Furfuryl Tetrahydropyranyladenine)
Based on positive results demonstrated in Pyratine-6™ clinical evaluations,
Senetek initiated a clinical trial of 0.125% Furfuryl Tetrahydropyranyladenine for
the reduction of visible signs and symptoms associated with various conditions
such as rosacea, eczema, contact dermatitis and menopause. Rosacea is a chronic
dermatosis afflicting more than 14 million people in North America and 45 million
people worldwide.
An overall clinical improvement was noted in 80% of subjects, including reduction
of erythema and papules. The investigators saw continual, statistically significant
mean improvement with Pyratine XR™ treatment, including a 90% improvement
in lesions, 45% improvement in erythema and a 28% improvement in
telangiectasia
Pyratine XR™ Crème and Lotion were launched in the North American Physician
market in March 2009.
The Company is actively seeking marketing collaboration agreements for other
geographies
Kinetin
Senetek scientists developed and patented the cytokinin Kinetin as an anti-aging
compound. Senetek commercialized Kinetin under the Kinerase® trademark, which
is now owned by Valeant Pharmaceuticals Inc. Kinerase® is currently the leading
anti-aging compound sold in the North American physician market. In early 2007,
Senetek sold Valeant a perpetual use license for Kinetin for $21 million,
forgiveness of a $6 million prepaid royalty credit reimbursement obligation that
Senetek otherwise would have owed to Valeant, and a right to share in future
royalties due to Valeant from other Kinetin licensees through 2011.

Invicorp®
Senetek has entered into a partnership agreement with Plethora Solutions
Limited (LSE-AIM: PLE), for the commercialization of Invicorp® in North
America. Under this agreement, Plethora assumes full financial responsibility
for all future development, regulatory approvals, and sales and marketing of the
product. Senetek will participate in the success of Invicorp® through milestone
payments and royalties based on net sales. The European marketing rights,
previously licensed to Ardana Biosciences Ltd, were returned to Senetek when
Ardana entered receivership in June 2008. An evaluation of the Company’s
options regarding redeployment of the European marketing rights as well as
rights for the rest of the world is currently underway.
Reliaject®
Reliaject® is an advanced drug delivery system for self-administration of
parenteral drugs, including epinephrine for emergency treatment of anaphylaxis,
a severe allergic reaction that occurs in response to food, insect venom or
medication – currently a $250 million market in North American alone.
Reliaject® is also well suited to other injectable therapies including Senetek’s
Invicorp® for the treatment of ED. The company entered an agreement with
Ranbaxy Pharmaceuticals, through which Senetek will receive future milestone
payments, as well as royalties paid out over 15 years on all products introduced
in the Reliaject® drug delivery system.
Research & Development
Senetek’s scientific research collaborations form the basis for a continuous,
interactive flow of new product identification, evaluation and testing activity
between the University of Aarhus, Senetek’s dedicated laboratory in Denmark,
the Institute of Experimental Botany in the Czech Republic, the University of
California-Irvine, and the Institute of Bioorganic Chemistry of the Polish
Academy of Sciences among others. Through these collaborations the Company
has greatly expanded its IP portfolio, adding many vital technologies, while
accelerating product development.
Pipeline
Senetek’s partnerships with leading research and academic institutions have
placed the Company at the forefront of technological advancements in the
science of aging. The Company’s large and growing IP portfolio features new
models in treatment that span a range of therapeutic areas including
dermatology, nutrition, wound healing and erectile dysfunction.
Market Opportunity
Owing to an increase in health awareness and continued progress in the field of
science and medicine, the average global life span has seen a steady rise over the
past several decades, a trend that is only expected to become more pronounced
in the decades to come. According to the United Nations, the percentage of the
world’s population over the age of 60 is expected to rise from 10.0% in 2000 to
22.1% in 2050. In more developed regions, such as Europe and North America,
these percentages are anticipated to be even higher, estimated at approximately
35.0% and 27.0%, respectively, by 2050. The aging of society is likely to create
increased opportunity for treatments and therapies such as those based on
Senetek’s patented compounds.
Business Model
With a strong balance sheet in place, the Company has transitioned from a
licensing model to a sales and marketing model, delivering an increased revenue
stream with higher margin potential and creating long-term value for its
shareholders.